Skip to Main Content

Advertisement

Umbrella Alt Text
header search
Search
Advanced Search
Skip Nav Destination

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung Cancer

Clin Cancer Res (2005) 11 (10): 3750–3757.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Case report: Neuroendocrine breast carcinoma with a germline EGFR T790M mutation
  • Olivia A. Sagan
  • Anna Rothstein
  • Bhaghyasree Jambunathan
  • Mersiha Hadziahmetovic
  • Anita Antoniolli
  • M. Hammad Rashid
Frontiers in Oncology (2023) 13
Overall Survival Benefits of First-Line Treatments for Asian Patients With Advanced EGFR-Mutated NSCLC Harboring L858R Mutation: A Systematic Review and Network Meta-Analysis
  • Sik-Kwan Chan
  • Horace Cheuk-Wai Choi
  • Victor Ho-Fun Lee
JTO Clinical and Research Reports (2022) 3 (5): 100322.
Identifying Drug Targets of Oral Squamous Cell Carcinoma through a Systems Biology Method and Genome-Wide Microarray Data for Drug Discovery by Deep Learning and Drug Design Specifications
  • Yi-Chung Lin
  • Bor-Sen Chen
International Journal of Molecular Sciences (2022) 23 (18): 10409.
The exploration of three different treatment models of osimertinib plus antiangiogenic agents in non‐small cell lung cancer: A real‐world study
  • Yu Feng
  • Liling Huang
  • Haohua Zhu
  • Le Tang
  • Xingsheng Hu
  • Yuankai Shi
Thoracic Cancer (2022) 13 (18): 2641.
Emerging Importance of Tyrosine Kinase Inhibitors against Cancer: Quo Vadis to Cure?
  • Raj Kumar Mongre
  • Chandra Bhushan Mishra
  • Arvind Kumar Shukla
  • Amresh Prakash
  • Samil Jung
  • Md Ashraf-Uz-Zaman
  • Myeong-Sok Lee
International Journal of Molecular Sciences (2021) 22 (21): 11659.
Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC
  • Daniela Ferreira
  • Juliana Miranda
  • Paula Martins-Lopes
  • Filomena Adega
  • Raquel Chaves
International Journal of Molecular Sciences (2021) 22 (8): 3815.
Association of hOGG1‐Cys variants with occurrence of p53 and EGFR deletion mutations in non‐small cell lung cancer
  • Ming‐Jenn Chen
  • Ching‐Ju Shen
  • Lee Wang
  • Po‐Ming Chen
  • Chih‐Yi Chen
  • Huei Lee
Thoracic Cancer (2021) 12 (4): 534.
A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632
  • Rintaro Noro
  • Satoshi Igawa
  • Akihiro Bessho
  • Takashi Hirose
  • Tsuneo Shimokawa
  • Masanao Nakashima
  • Koichi Minato
  • Nobuhiko Seki
  • Takaaki Tokito
  • Toshiyuki Harada
  • Shinji Sasada
  • Shingo Miyamoto
  • Yosuke Tanaka
  • Naoki Furuya
  • Takayuki Kaburagi
  • Hideki Hayashi
  • Hirotoshi Iihara
  • Hiroaki Okamoto
  • Kaoru Kubota
Lung Cancer (2021) 161: 49.

Assessment of Nine Driver Gene Mutations in Surgically Resected Samples from Patients with Non-Small-Cell Lung Cancer
  • Shuo Wang
  • Xiujuan Qu
  • Lili Cao
  • Xuejun Hu
  • Kezuo Hou
  • Yunpeng Liu
  • Xiaofang Che
Cancer Management and Research (2020) Volume 12: 4029.
Key prognostic factors for EGFR-mutated non-adenocarcinoma lung cancer patients in the Japanese Joint Committee of Lung Cancer Registry Database
  • Keigo Kobayashi
  • Kenzo Soejima
  • Koichi Fukunaga
  • Yasushi Shintani
  • Ikuo Sekine
  • Takehito Shukuya
  • Koichi Takayama
  • Akira Inoue
  • Isamu Okamoto
  • Katsuyuki Kiura
  • Kazuhisa Takahashi
  • Nobuyuki Yamamoto
  • Yuichi Takiguchi
  • Etsuo Miyaoka
  • Meinoshin Okumura
  • Ichiro Yoshino
Lung Cancer (2020) 146: 236.
Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns
  • Matthew Peters
  • Edward S. Kim
  • Vera Hirsch
Journal of Global Oncology (2019) (5): 1.
Prognostic implication of EGFR mutation status and subtype in resected lung adenocarcinoma patients irrespective of therapy
  • R. Li
  • Q. Li
  • S. Lin
  • W. Li
  • L. Yu
  • L. Wang
  • X. Dong
  • L. Yu
  • S. Li
  • W. Liu
  • B. Li
Clinical and Translational Oncology (2019) 21 (3): 298.
Detection of clinically relevant epidermal growth factor receptor pathway mutations in circulating cell-free tumor DNA using next generation sequencing in squamous cell carcinoma lung
  • Kanakasetty Babu Govind
  • Deepak Koppaka
  • Lokanatha Dasappa
  • Linu Abraham Jacob
  • Suresh M.C. Babu
  • N. Kadabur Lokesh
  • Rudresha Antapura Haleshappa
  • L.K. Rajeev
  • Smitha Carol Saldanha
  • Anand Abhishek
  • Vikas Asati
  • R. Chethan
  • Vedam Laxmi Ramprasad
South Asian Journal of Cancer (2019) 08 (04): 247.
Current Approaches in NSCLC Targeting K-RAS and EGFR
  • Veronica Aran
  • Jasminka Omerovic
International Journal of Molecular Sciences (2019) 20 (22): 5701.
Targeting Autophagy for Overcoming Resistance to Anti-EGFR Treatments
  • Yoojung Kwon
  • Misun Kim
  • Hyun Suk Jung
  • Youngmi Kim
  • Dooil Jeoung
Cancers (2019) 11 (9): 1374.
Influence of Amino Acid Mutations and Small Molecules on Targeted Inhibition of Proteins Involved in Cancer
  • V. Kanakaveti
  • P. Anoosha
  • R. Sakthivel
  • S.K. Rayala
  • M.M. Gromiha
Current Topics in Medicinal Chemistry (2019) 19 (6): 457.
Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer
  • Hideki Hayashi
  • Hirotoshi Iihara
  • Chiemi Hirose
  • Yoshihisa Fukuda
  • Mika Kitahora
  • Daizo Kaito
  • Komei Yanase
  • Junki Endo
  • Yasushi Ohno
  • Akio Suzuki
  • Tadashi Sugiyama
Lung Cancer (2019) 134: 1.
Added prognostic value of CT characteristics and IASLC/ATS/ERS histologic subtype in surgically resected lung adenocarcinomas
  • Young Joo Suh
  • Hyun-Ju Lee
  • Young Tae Kim
  • Chang Hyun Kang
  • In Kyu Park
  • Yoon Kyung Jeon
  • Doo Hyun Chung
Lung Cancer (2018) 120: 130.
Efficacy of thoracic radiotherapy in patients with stage IIIB–IV epidermal growth factor receptor-mutant lung adenocarcinomas who received and responded to tyrosine kinase inhibitor treatment
  • Yu-Chun Yen
  • Han-Lin Hsu
  • Jer-Hwa Chang
  • Wei-Cheng Lin
  • Yin-Chun Chang
  • Chia-Lun Chang
  • Jyh-Ming Chow
  • Kevin Sheng-Po Yuan
  • Alexander T.H. Wu
  • Szu-Yuan Wu
Radiotherapy and Oncology (2018) 129 (1): 52.
Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas
  • Ying Jin
  • Xun Shi
  • Jun Zhao
  • Qiong He
  • Ming Chen
  • Junrong Yan
  • Qiuxiang Ou
  • Xue Wu
  • Yang W. Shao
  • Xinmin Yu
Lung Cancer (2018) 124: 110.
Effect of postoperative systemic therapy on pulmonary adenocarcinoma with unexpected pleural spread detected during thoracotomy or thoracoscopy
  • Chi-Lu Chiang
  • Lei-Chi Wang
  • Hsiang-Ling Ho
  • Chun-Ming Tsai
  • Yi-Chen Yeh
  • Wen-Hu Hsu
  • Teh-Ying Chou
  • Chao-Hua Chiu
  • Yu-Chung Wu
Oncotarget (2018) 9 (4): 5435.
Efficacy of gefitinib in epidermal growth factor receptor-activating mutation-positive nonsmall cell lung cancer: Does exon 19 deletion differ from exon 21 mutation?
  • Amit Joshi
  • Vijay Patil
  • Vanita Noronha
  • Anuradha Chougule
  • Atanu Bhattacharjee
  • Rajiv Kumar
  • Supriya Goud
  • Sucheta More
  • Anant Ramaswamy
  • Ashay Karpe
  • Nikhil Pande
  • Arun Chandrasekharan
  • Alok Goel
  • Vikas Talreja
  • Abhishek Mahajan
  • Amit Janu
  • Nilendu Purandare
  • Kumar Prabhash
Lung India (2018) 35 (1): 27.
Activation of the EGF Receptor by Ligand Binding and Oncogenic Mutations: The “Rotation Model”
  • Endang Purba
  • Ei-ichiro Saita
  • Ichiro Maruyama
Cells (2017) 6 (2): 13.
Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis
  • Jingqi Zhuang
  • Yongfeng Yu
  • Ziming Li
  • Shun Lu
Oncotarget (2017) 8 (32): 53675.
Uncommon EGFR mutations in advanced non-small cell lung cancer
  • Grainne M. O’Kane
  • Penelope A. Bradbury
  • Ronald Feld
  • Natasha B. Leighl
  • Geoffrey Liu
  • Katherine-M. Pisters
  • Suzanne Kamel-Reid
  • Ming S. Tsao
  • Frances A. Shepherd
Lung Cancer (2017) 109: 137.
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for lung squamous carcinomas harboring EGFR mutation: A multicenter study and pooled analysis of published reports
  • Yongmei Liu
  • Yan Zhang
  • Li Zhang
  • Bin Liu
  • Yongsheng Wang
  • Xiaojuan Zhou
  • Yanying Li
  • Qian Zhao
  • Youling Gong
  • Lin Zhou
  • Jiang Zhu
  • Zhenyu Ding
  • Jin Wang
  • Feng Peng
  • Meijuan Huang
  • Lu Li
  • Li Ren
  • You Lu
Oncotarget (2017) 8 (30): 49680.
Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung
  • Yung‐Hung Luo
  • Chieh‐Hung Wu
  • Chu‐Yun Huang
  • Chih‐Wei Wu
  • Wen‐Shuo Wu
  • Yu‐Chin Lee
  • Jacqueline Whang‐Peng
  • Yuh‐Min Chen
Asia-Pacific Journal of Clinical Oncology (2017) 13 (5)
Detection of EGFR and BRAF mutations by competitive allele-specific TaqMan polymerase chain reaction in lung adenocarcinoma
  • Yang Yang
  • Yi Meng
  • Hang Zhang
  • Xiaoyan Shen
  • Rutian Li
  • Lixia Yu
  • Baorui Liu
  • Lifeng Wang
Oncology Letters (2017)
Chromogenic Assay for Lung Cancer-Related EGFR Exon 19 Hotspot Deletion Mutations
  • Andy K. Zhang
Genetic Testing and Molecular Biomarkers (2016) 20 (1): 18.
Molecular gene signature and prognosis of non-small cell lung cancer
  • Poyin Huang
  • Chiou-Ling Cheng
  • Ya-Hsuan Chang
  • Chia-Hsin Liu
  • Yi-Chiung Hsu
  • Jin-Shing Chen
  • Gee-Chen Chang
  • Bing-Ching Ho
  • Kang-Yi Su
  • Hsuan-Yu Chen
  • Sung-Liang Yu
Oncotarget (2016) 7 (32): 51898.
The effects of bufadienolides on HER2 overexpressing breast cancer cells
  • Tianjiao Wang
  • Lin Mu
  • Haifeng Jin
  • Peng Zhang
  • Yueyue Wang
  • Xiaochi Ma
  • Jinjin Pan
  • Jian Miao
  • Yuhui Yuan
Tumor Biology (2016) 37 (6): 7155.
EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China
  • Jianlin Xu
  • Bo Jin
  • Tianqing Chu
  • Xue Dong
  • Haitang Yang
  • Yanwei Zhang
  • Dan Wu
  • Yuqing Lou
  • Xueyan Zhang
  • Huiming Wang
  • Baohui Han
Lung Cancer (2016) 96: 87.
Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma
  • Young Wha Koh
  • Han Jo Kim
  • Hyog Young Kwon
  • Jae-Ho Han
  • Chi-Kyou Lee
  • Moon-Su Lee
  • Chang-Jin Kim
  • Moo-Jun Baek
  • Dongjun Jeong
Oncology (2016) 90 (5): 289.
The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
  • Yue-Lun Zhang
  • Jin-Qiu Yuan
  • Kai-Feng Wang
  • Xiao-Hong Fu
  • Xiao-Ran Han
  • Diane Threapleton
  • Zu-Yao Yang
  • Chen Mao
  • Jin-Ling Tang
Oncotarget (2016) 7 (48): 78985.
Thymoma and thymic carcinomas
  • Marta Scorsetti
  • Francesco Leo
  • Annalisa Trama
  • Rolando D’Angelillo
  • Danila Serpico
  • Marianna Macerelli
  • Paolo Zucali
  • Gemma Gatta
  • Marina Chiara Garassino
Critical Reviews in Oncology/Hematology (2016) 99: 332.
An epidermal growth factor receptor exon 19 mutation in a mucin-producing gastric cancer sample from a Chinese patient
  • Weipeng Lu
  • Mei Li
  • Hai Wang
  • Lina Liu
  • Shen Lu
Japanese Journal of Clinical Oncology (2016) 46 (6): 502.
Examining Treatment Outcomes with Erlotinib in Patients with Advanced Non–Small Cell Lung Cancer Whose Tumors Harbor Uncommon EGFR Mutations
  • Barbara Klughammer
  • Wolfram Brugger
  • Federico Cappuzzo
  • Tudor Ciuleanu
  • Tony Mok
  • Martin Reck
  • Eng Huat Tan
  • Paul Delmar
  • Gaëlle Klingelschmitt
  • Anny-Yue Yin
  • Olivia Spleiss
  • Lin Wu
  • David S. Shames
Journal of Thoracic Oncology (2016) 11 (4): 545.
Porocarcinomas harbor recurrent HRAS-activating mutations and tumor suppressor inactivating mutations
  • Paul W. Harms
  • Daniel H. Hovelson
  • Andi K. Cani
  • Kei Omata
  • Michaela J. Haller
  • Michael L. Wang
  • David Arps
  • Rajiv M. Patel
  • Douglas R. Fullen
  • Min Wang
  • Javed Siddiqui
  • Aleodor Andea
  • Scott A. Tomlins
Human Pathology (2016) 51: 25.
Mutational profiling of non-small-cell lung cancer patients resistant to first-generation EGFR tyrosine kinase inhibitors using next generation sequencing
  • Ying Jin
  • Yang Shao
  • Xun Shi
  • Guangyuan Lou
  • Yiping Zhang
  • Xue Wu
  • Xiaoling Tong
  • Xinmin Yu
Oncotarget (2016) 7 (38): 61755.
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations in China
  • Jianlin Xu
  • Yanwei Zhang
  • Bo Jin
  • Tianqing Chu
  • Xue Dong
  • Haitang Yang
  • Dan Wu
  • Yuqing Lou
  • Xueyan Zhang
  • Huiming Wang
  • Baohui Han
Journal of Cancer Research and Clinical Oncology (2016) 142 (6): 1325.
Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease
  • Jianchun Chen
  • Fenghua Zeng
  • Steven J. Forrester
  • Satoru Eguchi
  • Ming-Zhi Zhang
  • Raymond C. Harris
Physiological Reviews (2016) 96 (3): 1025.
Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
  • Jiang-Yong Yu
  • Si-Fan Yu
  • Shu-Hang Wang
  • Hua Bai
  • Jun Zhao
  • Tong-Tong An
  • Jian-Chun Duan
  • Jie Wang
Chinese Journal of Cancer (2016) 35 (1)
Covalent EGFR Inhibitors: Binding Mechanisms, Synthetic Approaches, and Clinical Profiles
  • Monia Hossam
  • Deena S. Lasheen
  • Khaled A. M. Abouzid
Archiv der Pharmazie (2016) 349 (8): 573.
The Association Between Tumor Epidermal Growth Factor Receptor (EGFR) Mutation and Multiple Primary Malignancies in Patients With Adenocarcinoma of the Lungs
  • Yung-Hung Luo
  • Hsiang-Ling Ho
  • Chun-Ming Tsai
  • Jen-Fu Shih
  • Chao-Hua Chiu
  • Shinn-Liang Lai
  • Yu-Chin Lee
  • Reury-Perng Perng
  • Jacqueline Whang-Peng
  • Teh-Ying Chou
  • Yuh-Min Chen
American Journal of Clinical Oncology (2015) 38 (2): 147.
Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial
  • Jack P. Wang
  • Chen-Yi Wu
  • Yi-Cheng Yeh
  • Yi-Ming Shyr
  • Ying-Ying Wu
  • Chen-Yu Kuo
  • Yi-Ping Hung
  • Ming-Huang Chen
  • Wei-Ping Lee
  • Jiing-Chyuan Luo
  • Yee Chao
  • Chung-Pin Li
Oncotarget (2015) 6 (20): 18162.
Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy
  • Jeffrey.S. Chang
  • Li-Tzong Chen
  • Yan-Shen Shan
  • Sheng-Fung Lin
  • Sheng-Yen Hsiao
  • Chia-Rung Tsai
  • Shu-Jung Yu
  • Hui-Jen Tsai
Medicine (2015) 94 (24): e969.
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3
  • Terufumi Kato
  • Hiroshige Yoshioka
  • Isamu Okamoto
  • Akira Yokoyama
  • Toyoaki Hida
  • Takashi Seto
  • Katsuyuki Kiura
  • Dan Massey
  • Yoko Seki
  • Nobuyuki Yamamoto
Cancer Science (2015) 106 (9): 1202.
Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
  • Feng-Che Kuan
  • Liang-Tseng Kuo
  • Min-Chi Chen
  • Cheng-Ta Yang
  • Chung-Sheng Shi
  • David Teng
  • Kuan-Der Lee
British Journal of Cancer (2015) 113 (10): 1519.
MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
  • Dario Presutti
  • Simonetta Santini
  • Beatrice Cardinali
  • Giuliana Papoff
  • Cristiana Lalli
  • Simone Samperna
  • Valentina Fustaino
  • Giuseppe Giannini
  • Giovina Ruberti
  • Jung Weon Lee
PLOS ONE (2015) 10 (11): e0143333.
Impact of Smoking Status on EGFR-TKI Efficacy for Advanced Non–Small-Cell Lung Cancer in EGFR Mutants: A Meta-analysis
  • Yaxiong Zhang
  • Shiyang Kang
  • Wenfeng Fang
  • Shaodong Hong
  • Wenhua Liang
  • Yue Yan
  • Tao Qin
  • Yanna Tang
  • Jin Sheng
  • Li Zhang
Clinical Lung Cancer (2015) 16 (2): 144.
  • Online ISSN 1557-3265
  • Print ISSN 1078-0432

AACR Journals

 

 

  • Copyright © 2023 by the American Association for Cancer Research.
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.
Accept